Regeneron Pharmaceuticals reported a 4% increase in second quarter 2025 revenues to $3.68 billion, with Dupixent global net sales rising 22% to $4.34 billion. EYLEA HD U.S. net sales increased 29% to $393 million. The company also received FDA approval for Lynozyfic for multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria. Regeneron’s oncology portfolio showed progress, with positive pivotal data for potential FDA approval of Libtayo in adjuvant CSCC. The company is confident in its pipeline and financial performance, with a 12% increase in non-GAAP EPS.

In terms of financials, Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends in the second quarter of 2025. The company also made significant investments in U.S. manufacturing and business development, totaling over $7 billion since the start of the year. Regeneron’s net product sales of EYLEA HD and EYLEA in the U.S. increased, but total net sales decreased due to competitive pressures. The company’s collaboration revenue saw a boost from increased profits associated with Dupixent sales.

Regeneron announced key pipeline progress, including FDA approvals for Dupixent in bullous pemphigoid and chronic spontaneous urticaria. The company also provided updates on its oncology programs, with Lynozyfic receiving accelerated approval for multiple myeloma. In-licensed rights to a late-stage GLP-1/GIP receptor agonist were also secured. The company continues to focus on driving innovation and value creation through its diverse pipeline and strategic investments.

Read more at GlobeNewswire: Regeneron Reports Second Quarter 2025 Financial and